MRK Merck & Co
- 131.200
- +0.480+0.37%
- 131.110
- -0.090-0.07%
Merck & Co News
Merck Is Maintained at Buy by Truist Securities
Merck Is Maintained at Buy by Truist Securities
Truist Securities Maintains Buy on Merck & Co, Raises Price Target to $143
Truist Securities analyst Robyn Karnauskas maintains Merck & Co with a Buy and raises the price target from $142 to $143.
Merck & Co Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/26/2024 8.83% Truist Securities $142 → $143 Maintains Buy 04/18/2024 2.74% Cantor Fitzgerald → $135 Rei
Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
Jefferies Adjusts Merck & Company Price Target to $150 From $145
Merck & Company (MRK) has an average rating of outperform and price targets ranging from $114 to $155, according to analysts polled by Capital IQ. Price: 131.18, Change: +0.46, Percent Change: +0.35
Investor Sentiment Improves Slightly, But Dow Tumbles Over 350 Points
The CNN Money Fear and Greed index showed a slight improvement in the overall market sentiment, while the index remained in the "Fear" zone on Thursday.U.S. stocks settled lower on Thursday, following
Express News | Damo: Raise Merck's target price to $132 and raise the 2024 profit forecast
Earnings Call Summary | Merck & Co(MRK.US) Q1 2024 Earnings Conference
The following is a summary of the Merck & Co., Inc. (MRK) Q1 2024 Earnings Call Transcript:Financial Performance:Total company revenues for Q1 2024 were $15.8 billion, up 9% or 12% excluding foreign e
US stocks closed | The three major indices collectively closed down. Nvidia reversed the market and rose nearly 4%, and Google rose more than 16% after the market
The S&P Index stopped three times in a row, the Dow fell two times in a row, Tesla rose 5%, fell 10% after Meta earnings report, the biggest decline in two years, Microsoft turned up and rose more than 5% after the market, and Intel fell 9% after the market.
Stocks Drop, Tech Tumbles With Meta's Weak Outlook, Q1 Stagflation Fears; Gold Miners Advance: What's Driving Markets Thursday?
Wall Street suffers a double blow in Thursday's session, as softer-than-expected revenue forecasts from Meta Platforms Inc. (NASDAQ:META) are being compounded by weaker-than-expected economic growth a
Cantor Fitzgerald Adjusts Merck & Co.' Price Target to $155 From $135, Keeps Overweight Rating
Merck & Co. (MRK) has an average rating of outperform and price targets ranging from $114 to $148, according to analysts polled by Capital IQ. Price: 130.00, Change: +3.00, Percent Change: +2.36
Top Midday Stories: Shares of Meta, IBM, Caterpillar, Comcast and Southwest Down Big Post-Earnings; AstraZeneca Shares See Post-Earnings Bump
All three major Wall Street indexes were down in late-morning trading as investors processed a GDP report that showed slower-than-anticipated growth with persistently high inflation and earnings miss
S&P 500 Down Over 1%; Merck Increases 2024 Outlook
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling by around 250 points on Thursday.The Dow traded down 1.55% to 37,864.79 while the NASDAQ fell 1.60% to 15,460.95. The
Merck (MRK) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
For the quarter ended March 2024, Merck (MRK) reported revenue of $15.78 billion, up 8.9% over the same period last year. EPS came in at $2.07, compared to $1.40 in the year-ago quarter.
Research Alert: CFRA Retains Buy View On Shares Of Merck & Co., Inc
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We lift our target to $146 from $137, 1
Changes in US stocks | MSD rose nearly 4%, Q1 net profit increased 69% year on year, raised full-year guidance
Glonghui on April 25 | MSD (MRK.US) rose 3.93% to $131.99. MSD's total global sales for the first quarter were US$15.8 billion, up 9% year on year; net profit was US$4.762 billion, up 69% year on year. The company expects full-year sales of $63.1 billion to $64.3 billion, compared to the previous forecast of $62.7 billion to $64.2 billion; the non-GAAP earnings per share range is $8.53 to $8.65, higher than the previous forecast of $8.44 to $8.59.
Rutgers Dual Degree Program Enabled Graduate Student to Pursue Interest in Healthcare While She Earned an MBA
The option of pursuing a Master's in Public Health and a Rutgers MBA was the "perfect fit."NEWARK, N.J., April 25, 2024 /PRNewswire/ -- After graduating from Cornell University, Daphni Sawyer worked
Merck Shares Climb After Higher-Than-Expected Sales of Cancer Drug Keytruda -- WSJ
By Peter Loftus Shares of U.S. drugmaker Merck are up about 2.5% in premarket trading after reporting that its blockbuster cancer drug Keytruda fueled a higher-than-expected increase in quarterly sal
We Think Merck (NYSE:MRK) Can Stay On Top Of Its Debt
Merck Lifts Full-Year 2024 Outlook Following First-Quarter Beat
Merck (MRK) on Thursday recorded better-than-expected first-quarter results boosted by sales of cancer immunotherapy Keytruda and human papillomavirus vaccine Gardasil, prompting the pharmaceutical gi
Analysis
Price Target
No Data
